Display Settings:

Format

Send to:

Choose Destination
    Vaccine. 2008 Jul 29;26(32):4057-61. Epub 2008 Jun 2.

    Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine.

    Source

    Vanderbilt University School of Medicine and Pediatrics, Vanderbilt University Medical Center, 1161 21st Avenue South, Nashville, TN 37232, USA. keipp.talbot@vanderbilt.edu

    Abstract

    To augment the available influenza vaccine supply, a phase III study was conducted to evaluate the immunogenicity, safety, and consistency of a new trivalent inactivated influenza vaccine manufactured by CSL Limited. Healthy adults (ages 18-64) were randomized to receive either a single dose of TIV from multi-dose vials with thimerosal, TIV from pre-filled syringes without thimerosal, or placebo. Of the TIV recipients, 97.8% achieved a post-vaccination titer > or =40 against H1N1, 99.9% against H3N2 component, and 94.2% against influenza B. Few local or systemic adverse events were noted after vaccination with either TIV presentation. TIV was well tolerated and immunogenic.

    PMID:
    18602726
    [PubMed - indexed for MEDLINE]
    PMCID: PMC2605420
    Free PMC Article

    Images from this publication.See all images (1) Free text

    Figure 1

      Supplemental Content

      Click here to read Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk